
Loading, please wait...

Loading, please wait...

Experts focused on individuals with abnormal amyloid-beta (Aβ) but low tau levels in Alzheimer's Disease (AD). Examining 397 Aβ+ individuals, the research found that low tau was relatively common in those on the AD pathway and was associated with older age, male sex, greater cardiovascular risk, and specific cognitive impacts. The findings have implications for selecting individuals for Aβ- and tau-modifying therapies.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Experts focused on individuals with abnormal amyloid-beta (Aβ) but low tau levels in Alzheimer's Disease (AD). Examining 397 Aβ+ individuals, the research found that low tau was relatively common in those on the AD pathway and was associated with older age, male sex, greater cardiovascular risk, and specific cognitive impacts. The findings have implications for selecting individuals for Aβ- and tau-modifying therapies.
2 months ago

Discover the crucial role of glymphatic dysfunction in stroke, where perivascular clearance failure and neuroinflammation exacerbate cerebral edema and post-stroke brain injury.
Today

A prenatal case highlights severe glutaric acidemia type II presenting as bilateral hyperechoic cystic kidneys at 18 weeks. Whole-exome sequencing revealed a novel homozygous ETFDH frameshift variant, demonstrating the power of rapid genetic testing in fetal renal anomalies.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday